MX390627B - Uso de pridopidina para el tratamiento de la disminucion funcional. - Google Patents
Uso de pridopidina para el tratamiento de la disminucion funcional.Info
- Publication number
- MX390627B MX390627B MX2019002265A MX2019002265A MX390627B MX 390627 B MX390627 B MX 390627B MX 2019002265 A MX2019002265 A MX 2019002265A MX 2019002265 A MX2019002265 A MX 2019002265A MX 390627 B MX390627 B MX 390627B
- Authority
- MX
- Mexico
- Prior art keywords
- functional capacity
- pridopidine
- functional
- decreasing
- treatment
- Prior art date
Links
- YGKUEOZJFIXDGI-UHFFFAOYSA-N pridopidine Chemical compound C1CN(CCC)CCC1C1=CC=CC(S(C)(=O)=O)=C1 YGKUEOZJFIXDGI-UHFFFAOYSA-N 0.000 title abstract 3
- 229950003764 pridopidine Drugs 0.000 title abstract 3
- 230000003247 decreasing effect Effects 0.000 title 1
- 230000007423 decrease Effects 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Psychology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662379175P | 2016-08-24 | 2016-08-24 | |
| US201662395263P | 2016-09-15 | 2016-09-15 | |
| US201662411511P | 2016-10-21 | 2016-10-21 | |
| US201662416685P | 2016-11-02 | 2016-11-02 | |
| PCT/US2017/048461 WO2018039477A1 (en) | 2016-08-24 | 2017-08-24 | Use of pridopidine for treating functional decline |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019002265A MX2019002265A (es) | 2019-10-30 |
| MX390627B true MX390627B (es) | 2025-03-21 |
Family
ID=61241181
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019002265A MX390627B (es) | 2016-08-24 | 2017-08-24 | Uso de pridopidina para el tratamiento de la disminucion funcional. |
| MX2022003072A MX2022003072A (es) | 2016-08-24 | 2019-02-25 | Uso de pridopidina para el tratamiento de la disminucion funcional. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022003072A MX2022003072A (es) | 2016-08-24 | 2019-02-25 | Uso de pridopidina para el tratamiento de la disminucion funcional. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11207310B2 (https=) |
| EP (2) | EP3504187B8 (https=) |
| JP (2) | JP6912574B2 (https=) |
| CN (2) | CN109923102B (https=) |
| AU (2) | AU2017315783C1 (https=) |
| BR (1) | BR112019003732A2 (https=) |
| CA (2) | CA3151507C (https=) |
| CL (2) | CL2019000485A1 (https=) |
| DK (1) | DK3504187T3 (https=) |
| ES (1) | ES3025836T3 (https=) |
| FI (1) | FI3504187T3 (https=) |
| HU (1) | HUE071008T2 (https=) |
| IL (1) | IL311081A (https=) |
| MX (2) | MX390627B (https=) |
| PL (1) | PL3504187T3 (https=) |
| PT (1) | PT3504187T (https=) |
| WO (1) | WO2018039477A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG188298A1 (en) | 2010-09-03 | 2013-04-30 | Ivax Int Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| PE20160195A1 (es) | 2013-06-21 | 2016-05-14 | Teva Pharmaceuticals Int Gmbh | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| TW201613859A (en) * | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| EP4282479A3 (en) | 2015-02-25 | 2024-02-21 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to treat depression or anxiety |
| US11471449B2 (en) | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
| ES3025836T3 (en) | 2016-08-24 | 2025-06-09 | Prilenia Neurotherapeutics Ltd | Use of pridopidine for treating functional decline |
| WO2018039475A1 (en) | 2016-08-24 | 2018-03-01 | Teva Pharmaceuticals International Gmbh | Use of pridopidine for treating dystonias |
| NZ750416A (en) | 2016-09-15 | 2022-04-29 | Boehringer Ingelheim Int | Heteroaryl carboxamide compounds as inhibitors of ripk2 |
| US12102627B2 (en) | 2016-09-16 | 2024-10-01 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating rett syndrome |
| AU2018329628B2 (en) | 2017-09-08 | 2021-04-22 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| US12036213B2 (en) | 2017-09-08 | 2024-07-16 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| EP3917380B1 (en) * | 2019-01-31 | 2025-03-19 | F. Hoffmann-La Roche AG | Assessing progression of huntington's disease |
| EP3920924A4 (en) | 2019-02-04 | 2022-11-16 | Prilenia Neurotherapeutics Ltd. | LOW-DOSE PRIDOIDIN FOR THE TREATMENT OF PARKINSON'S DISEASE AND OTHER PARKINSONIC-RELATED DISEASES |
| JP7436524B2 (ja) * | 2019-06-12 | 2024-02-21 | プリレニア ニューロセラピューティクス リミテッド | ハンチントン病及びその症状を治療するためのプリドピジン及びその類似体を含む組成物 |
| CN115551505B (zh) * | 2020-05-04 | 2026-03-17 | 普瑞尼亚神经治疗有限公司 | 使用选择性s1r激动剂治疗病毒性感染、疾病或病症 |
| WO2022219637A1 (en) * | 2021-04-14 | 2022-10-20 | Prilenia Neurotherapeutics Ltd. | Treatment of prodromal huntington disease |
| WO2025164698A1 (ja) * | 2024-01-31 | 2025-08-07 | 株式会社ケイファーマ | ハンチントン病治療剤及び治療用組成物 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9702716D0 (sv) | 1997-07-15 | 1997-07-15 | Ross Nicholas Waters | Substituted phenylazacycloalkanes in the treatment of cognitive disorders |
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| SE9904724D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| WO2005053703A1 (en) * | 2003-12-02 | 2005-06-16 | Leslie James Sheldon | Combination therapy for dementia, depression and apathy |
| GT200500063A (es) | 2004-04-01 | 2005-10-14 | Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias | |
| CA2584831C (en) | 2004-10-13 | 2013-09-17 | Neurosearch Sweden Ab | Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine |
| DOP2006000273A (es) | 2005-12-08 | 2007-10-15 | Aventis Pharma Inc | Uso de un antagonista de cb1 para tratar efectos secundarios y sintomas negativos de la esquizofrenia |
| EP1815857A1 (en) | 2006-02-02 | 2007-08-08 | LEK Pharmaceuticals D.D. | A pharmaceutical composition comprising perindopril |
| US20070286902A1 (en) | 2006-06-07 | 2007-12-13 | Abrika Pharmaceuticals | Dosage forms comprising a short acting sedative-hypnotic or salt thereof |
| SI2146961T1 (sl) | 2007-04-12 | 2014-08-29 | IVAX International GmbH | N-oksidni in/ali di-N-oksidni derivati stabilizatorjev/modulatorjev dopaminskega receptorja, ki izkazujejo izboljšane profile kardiovaskularnih stranskih učinkov |
| US8669048B2 (en) * | 2008-06-24 | 2014-03-11 | Parkinson's Institute | Pluripotent cell lines and methods of use thereof |
| US8384755B2 (en) | 2009-08-26 | 2013-02-26 | Intouch Technologies, Inc. | Portable remote presence robot |
| DK2480218T3 (da) | 2009-09-24 | 2020-08-24 | Capsugel Belgium Nv | Syreresistente kapsler |
| US20110206782A1 (en) | 2010-02-24 | 2011-08-25 | Auspex Pharmaceuticals, Inc. | Piperidine modulators of dopamine receptor |
| WO2011107583A1 (en) * | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
| CN103080343A (zh) | 2010-07-02 | 2013-05-01 | Skf公司 | 机械部件和用于表面硬化的方法 |
| SG188298A1 (en) | 2010-09-03 | 2013-04-30 | Ivax Int Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| US8703763B2 (en) | 2011-03-02 | 2014-04-22 | Hoffmann-La Roche Inc. | Bridged piperidine derivatives |
| WO2012159079A1 (en) | 2011-05-18 | 2012-11-22 | The Parkinson's Institute | Assay to determine lrrk2 activity in parkinson's disease |
| CN103958469B (zh) | 2011-09-07 | 2016-04-20 | 梯瓦制药国际有限责任公司 | 一种新的普利多匹定盐酸盐多晶型形态 |
| MX347209B (es) | 2011-12-08 | 2017-04-19 | Teva Pharmaceuticals Int Gmbh | La sal de bromhidrato de pridopidina. |
| US9744155B2 (en) * | 2012-03-28 | 2017-08-29 | Ixcela, Inc. | IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk |
| HK1206297A1 (en) | 2012-04-04 | 2016-01-08 | Teva Pharmaceuticals International Gmbh | Pharmaceutical compositions for combination therapy |
| EP2900226A4 (en) | 2012-09-27 | 2016-03-30 | Teva Pharma | COMBINATION OF RASAGILIN AND PRIDOPIDIN FOR TREATING NEURODEGENERATIVE DISORDERS, ESPECIALLY HUNTINGTON'S DISEASE |
| HK1211525A1 (en) | 2012-09-27 | 2016-05-27 | Teva Pharmaceutical Industries Ltd. | Laquinimod and pridopidine for treating neurodegenerative disorders |
| PE20160195A1 (es) * | 2013-06-21 | 2016-05-14 | Teva Pharmaceuticals Int Gmbh | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| PE20161220A1 (es) | 2014-01-22 | 2016-11-23 | Teva Pharmaceuticals Int Gmbh | Formulaciones de pridopidina de liberacion modificada |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| EP3236964A4 (en) | 2014-12-22 | 2018-09-19 | Teva Pharmaceuticals International GmbH | L-tartrate salt of pridopidine |
| EP4282479A3 (en) * | 2015-02-25 | 2024-02-21 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to treat depression or anxiety |
| WO2016138135A1 (en) | 2015-02-25 | 2016-09-01 | Teva Pharmaceuticals International Gmbh | Sigma-1 receptor modulators for treating huntington's disease |
| CA2993183A1 (en) | 2015-07-22 | 2017-01-26 | Teva Pharmaceuticals International Gmbh | Pridopidine base formulations and their use |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| WO2017048457A1 (en) | 2015-09-18 | 2017-03-23 | Teva Pharmaceuticals Industries Ltd. | Combination of laquinimod and pridopidine to treat multiple sclerosis |
| US11738012B2 (en) | 2016-02-24 | 2023-08-29 | Prilenia Neurotherapeutics Ltd. | Treatment of neurodegenerative eye disease using pridopidine |
| WO2018039475A1 (en) | 2016-08-24 | 2018-03-01 | Teva Pharmaceuticals International Gmbh | Use of pridopidine for treating dystonias |
| ES3025836T3 (en) | 2016-08-24 | 2025-06-09 | Prilenia Neurotherapeutics Ltd | Use of pridopidine for treating functional decline |
| AU2017326436A1 (en) | 2016-09-15 | 2019-04-11 | Prilenia Neurotherapeutics Ltd | Use of pridopidine for the treatment of anxiety and depression |
| WO2018053275A1 (en) | 2016-09-16 | 2018-03-22 | Teva Pharmaceuticals International Gmbh | Use of pridopidine for the treatment of familial dysautonomia |
| ES2909557T3 (es) | 2016-09-16 | 2022-05-09 | Prilenia Neurotherapeutics Ltd | Utilización de la pridopidina para el tratamiento del síndrome de Rett |
| CA3050700C (en) | 2017-01-20 | 2023-10-03 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for the treatment of fragile x syndrome |
| HRP20251431T1 (hr) | 2017-08-14 | 2026-01-02 | Prilenia Neurotherapeutics Ltd. | Liječenje amiotrofične lateralne skleroze pridopidinom |
| EP3675830A1 (en) | 2017-08-30 | 2020-07-08 | Prilenia Neurotherapeutics Ltd. | High concentration dosage forms of pridopidine |
-
2017
- 2017-08-24 ES ES17844433T patent/ES3025836T3/es active Active
- 2017-08-24 EP EP17844433.7A patent/EP3504187B8/en active Active
- 2017-08-24 AU AU2017315783A patent/AU2017315783C1/en active Active
- 2017-08-24 MX MX2019002265A patent/MX390627B/es unknown
- 2017-08-24 WO PCT/US2017/048461 patent/WO2018039477A1/en not_active Ceased
- 2017-08-24 CN CN201780066778.4A patent/CN109923102B/zh active Active
- 2017-08-24 CA CA3151507A patent/CA3151507C/en active Active
- 2017-08-24 IL IL311081A patent/IL311081A/en unknown
- 2017-08-24 JP JP2019531547A patent/JP6912574B2/ja active Active
- 2017-08-24 HU HUE17844433A patent/HUE071008T2/hu unknown
- 2017-08-24 BR BR112019003732-2A patent/BR112019003732A2/pt not_active Application Discontinuation
- 2017-08-24 CA CA3035092A patent/CA3035092C/en active Active
- 2017-08-24 PT PT178444337T patent/PT3504187T/pt unknown
- 2017-08-24 PL PL17844433.7T patent/PL3504187T3/pl unknown
- 2017-08-24 EP EP25152698.4A patent/EP4516356A3/en active Pending
- 2017-08-24 FI FIEP17844433.7T patent/FI3504187T3/fi active
- 2017-08-24 DK DK17844433.7T patent/DK3504187T3/da active
- 2017-08-24 US US15/685,993 patent/US11207310B2/en active Active
- 2017-08-24 CN CN202211419342.8A patent/CN115671103A/zh active Pending
-
2019
- 2019-02-22 CL CL2019000485A patent/CL2019000485A1/es unknown
- 2019-02-25 MX MX2022003072A patent/MX2022003072A/es unknown
- 2019-12-31 CL CL2019003924A patent/CL2019003924A1/es unknown
-
2020
- 2020-08-27 AU AU2020223736A patent/AU2020223736B2/en active Active
-
2021
- 2021-05-06 JP JP2021078504A patent/JP2021119186A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX390627B (es) | Uso de pridopidina para el tratamiento de la disminucion funcional. | |
| MX384234B (es) | Uso de pridopidina para el tratamiento de enfermedad de huntington. | |
| MX2024010140A (es) | Nuevos metodos. | |
| MX2021004639A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos. | |
| MX2020004467A (es) | Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r. | |
| CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
| MX378579B (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| MX2019003173A (es) | Terapia de combinacion con agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada. | |
| MX2021013139A (es) | Composicion farmaceutica para la prevencion y/o tratamiento de dermatitis atopica que comprende antagonista de interleucina 31 (il-31) como ingrediente activo. | |
| CR20180253A (es) | Composiciones terapéuticas para el tratamiento del virus de unmunodeficiencia humana | |
| MX2023014492A (es) | Compuestos utiles en la terapia para el vih. | |
| EA201492010A1 (ru) | Применение высокой дозы лахинимода для лечения рассеянного склероза | |
| SG10201805267UA (en) | Piperazine derivatives having multimodal activity against pain | |
| MX381440B (es) | Composicion farmaceutica para tratar colitis ulcerativa. | |
| TW201613578A (en) | Pharmaceutical combinations | |
| PH12016502352A1 (en) | Pharmaceutical composition | |
| MX379253B (es) | Formulaciones de oximetazolina estabilizadas y sus usos. | |
| MX374938B (es) | Un método para el tratamiento de trastornos del movimiento con befiradol. | |
| BR112015010223A2 (pt) | compostos tricíclicos para o uso no tratamento e/ou controle de obesidade | |
| MX2019009909A (es) | Composiciones farmaceuticas para terapia de combinacion. | |
| BR112015015938A2 (pt) | uso de cloridrato de fenilefrina e paracetamol, medicamento, método de tratamento de congestão das mucosas do trato respiratório superior em um humano adulto | |
| ECSP19024033A (es) | Composiciones de tesofensina | |
| MX2018004774A (es) | Derivados de morfolina sustituidos que tienen actividad contra el dolor. | |
| MX384394B (es) | Compuesto para uso en la prevención y tratamiento de enfermedades neurodegenerativas. | |
| EA202090416A1 (ru) | Способы лечения симптомов гастропареза с использованием велусетрага |